MET and non-small cell lung carcinoma: Wu et al. discovered a new type of dual inhibitor of EGFR and hepatocyte growth factor receptor (cMET), N19, which simultaneously degrades two proteins through the ubiquitin–proteasome, effectively overcoming gefitinib resistance in EGFR mutant NSCLC cells [28].